GSK Airs Phase III Data For Weekly GLP-1 Albiglutide, Plans To File By Year-End

GSK/Human Genome Sciences’ once-weekly injectable GLP-1 agonist albiglutide succeeds in a non-inferiority study and should be filed in late 2012. But analysts critique efficacy relative to the competition and some say the diabetes drug will come to the market too late.